Starpharma Holdings (SPHRY) Fair Value & Analysis
Healthcare · US · Market cap $221M
Starpharma Holdings
SPHRY · US
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 14 days ago
Fair value updated Jun 24, 2026 — revised from $1.41 to $1.40 (−0.7%) since Jun 23, 2026. Share price −6.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.6618 – $5.99 · fair‑value band $1.05 – $1.75 · the $5.00 price screens above the $1.40 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Starpharma Holdings (SPHRY) currently trades at $5.00, while our model-based Fair Value estimate is $1.40 — implying the stock looks roughly 72.0% overvalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Starpharma Holdings generated revenue of $14.6M at a net margin of -22.2%. It earns a return on equity of -14.5%. Fundamentals as of Jun 24, 2026
Our scenario range runs from $1.05 (bear case) to $1.75 (bull case); at $5.00, the current price sits above that range. The share trades about 12% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside — at -72%, SPHRY screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Starpharma Holdings reported revenue of $4.9M in FY2025 versus $1.8M in FY2021, a compound +28.6%/yr. Reported net income was −$10.0M in FY2025.
Is SPHRY fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Starpharma Holdings (SPHRY) undervalued?
What is the fair value of SPHRY?
What is the quality score of SPHRY?
What is the revenue of Starpharma Holdings (SPHRY)?
What is the net profit margin of SPHRY?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.